Effects of simvastatin/ezetimibe on microparticles, endothelial progenitor cells and platelet aggregation in subjects with coronary heart disease under antiplatelet therapy

AUTOR(ES)

Camargo, L.M., França, C.N., Izar, M.C., Bianco, H.T., Lins, L.S., Barbosa, S.P., Pinheiro, L.F., Fonseca, F.A.H.

FONTE

Braz J Med Biol Res

DATA DE PUBLICAÇÃO

15/04/2014

RESUMO

It is not known whether the addition of ezetimibe to statins adds cardiovascular protection beyond the expected changes in lipid levels. Subjects with coronary heart disease were treated with four consecutive 1-week courses of therapy (T) and evaluations. The courses were: T1, 100 mg aspirin alone; T2, 100 mg aspirin and 40 mg simvastatin/10 mg ezetimibe; T3, 40 mg simvastatin/10 mg ezetimibe, and 75 mg clopidogrel (300 mg initial loading dose); T4, 75 mg clopidogrel alone. Platelet aggregation was examined in whole blood. Endothelial microparticles (CD51), platelet microparticles (CD42/CD31), and endothelial progenitor cells (CD34/CD133; CDKDR/CD133, or CD34/KDR) were quantified by flow cytometry. Endothelial function was examined by flow-mediated dilation. Comparisons between therapies revealed differences in lipids (T2 and T3T1 and T4, P=0.001). Decreased platelet aggregation was observed after aspirin (arachidonic acid, T1

Documentos Relacionados

• Efeitos pleiotrópicos com reduções equivalentes do LDL-colesterol: estudo comparativo entre sinvastatina e associação sinvastatina/azetimiba
• Inflammation and circulating endothelial progenitor cells in patients with coronary artery disease and residual platelet reactivity
• Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia
• Effects of ergotamine and methysergide on blood platelet aggregation responses of migrainous subjects
• Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy